<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03873948</url>
  </required_header>
  <id_info>
    <org_study_id>12-16</org_study_id>
    <nct_id>NCT03873948</nct_id>
  </id_info>
  <brief_title>Evaluation of Arginine in Periodontal and Cardiovascular Disease</brief_title>
  <official_title>Analysis of Serum and Salivary ADMA-Arginine Levels in Patients With Periodontal and Cardiovascular Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Messina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Messina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asymmetric dimethylarginine (ADMA) plays a key role in endothelial function and may be a link
      for the known interaction of periodontitis and coronary heart disease (CHD). The
      investigators compared the impact of gingival health, periodontitis (CP), CHD or of both
      diseases (CP+CHD) on saliva and serum ADMA levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study was to evaluate a possible association between both saliva and serum
      ADMA levels in patients with CP and with CHD and if the serum ADMA levels are mediated by
      serum CRP.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 6, 2014</start_date>
  <completion_date type="Actual">March 1, 2019</completion_date>
  <primary_completion_date type="Actual">August 8, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Attachment level</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">141</enrollment>
  <condition>Metabolic Disorder</condition>
  <condition>Arginine; Hyperaminoaciduria</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Healthy patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Periodontitis</arm_group_label>
    <description>Patients with periodontal disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cardiovascular</arm_group_label>
    <description>Patients with cardiovascular disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Periodontitis+Cardiovascular</arm_group_label>
    <description>Patients with both periodontal and cardiovascular disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation of arginine serum level</intervention_name>
    <description>correlation of serum arginine level with periodontal and cardiovascular disease</description>
    <arm_group_label>Cardiovascular</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Periodontitis</arm_group_label>
    <arm_group_label>Periodontitis+Cardiovascular</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Thus, for this study, 35 patients with CP, 36 patients with CHD, 35 patients with CP+CHD,
        and 35 healthy subjects will finally enrolled.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of at least 16 teeth

          -  CP with a minimum of 40% of sites with a clinical attachment level (CAL) ≥2mm and
             probing depth (PD) ≥4mm;

          -  Presence of at least ≥2 mm of crestal alveolar bone loss verified on digital
             periapical radiographs

          -  Presence of ≥40% sites with bleeding on probing (BOP)

        Exclusion Criteria:

          -  Intake of contraceptives

          -  Intake of immunosuppressive or anti-inflammatory drugs throughout the last three
             months prior to the study

          -  Status of pregnancy or lactation

          -  Previous history of excessive drinking

          -  Allergy to local anaesthetic

          -  Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin,
             Nifedipine, Cyclosporin A or similar drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Messina</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 9, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>October 3, 2019</last_update_submitted>
  <last_update_submitted_qc>October 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Messina</investigator_affiliation>
    <investigator_full_name>Gaetano Isola, DDS, PhD</investigator_full_name>
    <investigator_title>Junior Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all collected IPD, all IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>10 years at least</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

